G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, AltersIn vitroEndothelial Cell Growth and Tubular Morphogenesis
Open Access
- 15 April 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (8), 2797-2807
- https://doi.org/10.1158/1078-0432.ccr-08-2610
Abstract
Purpose: We examined the effects of G3139 on the interaction of heparin-binding proteins [e.g., fibroblast growth factor 2 (FGF2) and collagen I] with endothelial cells. G3139 is an 18-mer phosphorothioate oligonucleotide targeted to the initiation codon region of the Bcl-2 mRNA. A randomized, prospective global phase III trial in advanced melanoma (GM301) has evaluated G3139 in combination with dacarbazine. However, the mechanism of action of G3139 is incompletely understood because it is unlikely that Bcl-2 silencing is the sole mechanism for chemosensitization in melanoma cells. Experimental Design: The ability of G3139 to interact with and protect heparin-binding proteins was quantitated. The effects of G3139 on the binding of FGF2 to high-affinity cell surface receptors and the induction of cellular mitogenesis and tubular morphogenesis in HMEC-1 and human umbilical vascular endothelial cells were determined. Results: G3139 binds with picomolar affinity to collagen I. By replacing heparin, the drug can potentiate the binding of FGF2 to FGFR1 IIIc, and it protects FGF from oxidation and proteolysis. G3139 can increase endothelial cell mitogenesis and tubular morphogenesis of HMEC-1 cells in three-dimensional collagen gels, increases the mitogenesis of human umbilical vascular endothelial cells similarly, and induces vessel sprouts in the rat aortic ring model. Conclusions: G3139 dramatically affects the behavior of endothelial cells. There may be a correlation between this observation and the treatment interaction with lactate dehydrogenase observed clinically.Keywords
This publication has 49 references indexed in Scilit:
- Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive diseaseBlood, 2008
- Level of endothelial cell apoptosis required for a significant decrease in microvessel densityExperimental Cell Research, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma CellsClinical Cancer Research, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Small Interfering RNA Targeting Bcl-2 Sensitizes Malignant MelanomaOligonucleotides, 2003
- Bcl‐2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF‐1mediated transcriptional activityThe FASEB Journal, 2002
- Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrixBiochemistry, 1992
- Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells invitro: Implications for a role of heparinase-like enzymes in the neovascular responseBiochemical and Biophysical Research Communications, 1987
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973